ID 56172
JaLCDOI
FullText URL
Author
Iwamoto, Takayuki Department of Breast and Endocrine Surgery, Okayama University Hospital
Taira, Naruto Department of Breast and Endocrine Surgery, Okayama University Hospital
Fujisawa, Tomomi Department of Breast Oncology, Gunma Prefectural Cancer Center
Araki, Kazuhiro Department of Breast Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research
Sakamaki, Kentaro Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo
Sangai, Takafumi Department of Breast and Thyroid Surgery, Chiba University Hospital
Kikawa, Yuichiro Department of Breast Surgery, Kobe City Medical Center General Hospital
Shien, Tadahiko Department of Breast and Endocrine Surgery, Okayama University Hospital
Takao, Shintaro Department of Breast Surgery, Hyogo Cancer Center
Sato, Masako Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center
Goto, Yoshinari Department of Breast Surgery, Ota Memorial Hospital
Yoshida, Takashi Department of Breast Surgery, Ota Memorial Hospital
Takahashi, Masato Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center
Aihara, Tomohiko Breast Center, Aihara Hospital
Mukai, Hirofumi Division of Breast and Medical Oncology, National Cancer Center Hospital East
Abstract
The Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study is a multicenter observational study evaluating the efficacy and safety of secondary endocrine therapy (ET) for postmenopausal cases of metastatic breast cancer (MBC) with poor response to primary ET. In this initial report we analyze the HORSE-BC baseline data to clarify the current status of treatment selection for MBC in Japan. Baseline data for the 50 patients enrolled in HORSE-BC were analyzed, including patient characteristics, types of secondary ET, and reasons for selecting secondary ET. Postoperative recurrence was detected in 84% of patients (42/50) and de novo stage IV breast cancer in 16% (8/50). Forty-one patients (41/50; 82%) received fulvestrant, 5 patients (10%) received selective estrogen receptor modulators (SERMs), 3 patients (6%) received ET plus a mammalian target of rapamycin (mTOR) inhibitor, and 1 patient received an aromatase inhibitor (AI) as the secondary ET. Forty-five patients selected their secondary ET based on its therapeutic effect, while 14 patients selected it based on side effects. Most patients with progression after primary ET selected fulvestrant as the secondary ET based on its therapeutic and side effects. We await the final results from the HORSE-BC study.
Keywords
breast cancer
secondary endocrine therapy
low sensitivity
primary endocrine therapy
fulvestrant
Amo Type
Original Article
Published Date
2018-08
Publication Title
Acta Medica Okayama
Volume
volume72
Issue
issue4
Publisher
Okayama University Medical School
Start Page
369
End Page
374
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2018 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID